Teva Pharmaceutical Industries (TEVA) stock plummeted over 11% in intraday trading on Wednesday, following the company's disappointing fourth-quarter earnings results and a gloomy outlook for 2025.
The Israeli pharmaceutical giant reported a significant decline in its Q4 non-GAAP earnings per share and revenue compared to the same period last year. TEVA's non-GAAP EPS for the quarter stood at $0.71, down from $1.00 a year earlier, while its revenue fell to $4.23 billion from $4.46 billion. Although the EPS met analysts' expectations, the revenue missed their forecast of $4.15 billion.
Moreover, TEVA's guidance for the full year 2025 fell short of analysts' projections. The company expects its 2025 non-GAAP diluted EPS to be in the range of $2.35 to $2.65 on revenue of $16.8 billion to $17.4 billion. Analysts had forecasted a non-GAAP EPS of $2.96 on revenue of $17.09 billion.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。